InsiderClue
Insiders · Profile

Cox John

CEO & President at Dyne Therapeutics · Director at REPLIGEN · EVP Pharmaceutical Oper & Tech at Biogen. Filing since 28 Oct 2010. CIK 0001498428

DYN Dyne Therapeutics, Inc. CEO & President · 11 trades RGEN REPLIGEN CORP Director · 4 trades BIIB Biogen EVP Pharmaceutical Oper & Tech · 11 trades
Company
Date
Role
Action
Shares
Amount
Of holding
DYN Dyne Therapeutics, Inc.
8 Sep 2026
CEO & President
Sold on a plan
5,658
$106.82K
1.6%
DYN Dyne Therapeutics, Inc.
13 Aug 2026
CEO & President
Sold on a plan
4,986
$131.03K
1.4%
DYN Dyne Therapeutics, Inc.
16 Jun 2026
CEO & President
Sold on a plan
2,683
$49.18K
0.7%
DYN Dyne Therapeutics, Inc.
13 May 2026
CEO & President
Sold on a plan
3,311
$60.79K
0.9%
DYN Dyne Therapeutics, Inc.
5 Mar 2026
CEO & President
Sold on a plan
2,732
$40.71K
0.7%
DYN Dyne Therapeutics, Inc.
5 Dec 2025
CEO & President
Sold on a plan
2,662
$55.16K
1.3%
DYN Dyne Therapeutics, Inc.
5 Sep 2025
CEO & President
Sold on a plan
2,640
$35.40K
1.3%
DYN Dyne Therapeutics, Inc.
14 Jul 2025
CEO & President
Bought
100,000
$911.00K
70.3%
DYN Dyne Therapeutics, Inc.
5 Jun 2025
CEO & President
Sold on a plan
4,060
$54.20K
2.8%
DYN Dyne Therapeutics, Inc.
5 Mar 2025
CEO & President
Sold on a plan
4,061
$48.04K
2.7%
DYN Dyne Therapeutics, Inc.
4 Sep 2024
CEO & President
Bought
32,000
$1.06M
opened
RGEN REPLIGEN CORP
24 Mar 2020
Director
Sold, plan not stated
1,858
$179.71K
66.8%
RGEN REPLIGEN CORP
18 Mar 2020
Director
Sold, plan not stated
26,736
$2.55M
90.6%
RGEN REPLIGEN CORP
4 Mar 2020
Director
Sold, plan not stated
10,000
$933.90K
78.2%
RGEN REPLIGEN CORP
24 Feb 2020
Director
Sold, plan not stated
4,455
$413.45K
61.6%
BIIB Biogen
25 Mar 2015
EVP Pharmaceutical Oper & Tech
Sold, plan not stated
12,010
$5.39M
32.0%
BIIB Biogen
1 Nov 2011
EVP Pharmaceutical Oper & Tech
Sold, plan not stated
2,175
$248.75K
18.5%
BIIB Biogen
21 Apr 2011
EVP Pharmaceutical Oper & Tech
Sold, plan not stated
4,350
$435.00K
29.6%
BIIB Biogen
13 Apr 2011
EVP Pharmaceutical Oper & Tech
Sold, plan not stated
36,234
$2.90M
77.8%
BIIB Biogen
11 Apr 2011
EVP Pharmaceutical Oper & Tech
Sold, plan not stated
6,900
$538.20K
40.0%
BIIB Biogen
31 Mar 2011
EVP Pharmaceutical Oper & Tech
Sold, plan not stated
2,840
$207.32K
22.4%
BIIB Biogen
2 Mar 2011
EVP Pharmaceutical Oper & Tech
Sold, plan not stated
4,041
$283.26K
29.2%
BIIB Biogen
17 Feb 2011
EVP Pharmaceutical Oper & Tech
Sold, plan not stated
1,843
$123.62K
11.9%
BIIB Biogen
9 Nov 2010
EVP Pharmaceutical Oper & Tech
Sold, plan not stated
773
$48.60K
4.5%
BIIB Biogen
2 Nov 2010
EVP Pharmaceutical Oper & Tech
Sold, plan not stated
765
$48.23K
4.3%
BIIB Biogen
28 Oct 2010
EVP Pharmaceutical Oper & Tech
Sold, plan not stated
6,900
$434.70K
27.4%
26 decisions on file.